氯吡格雷联合低分子肝素和拜阿司匹林治疗动静脉内瘘血栓形成的临床疗效

Clopidogrel combined with low molecular weight heparin and Clinical efficacy of aspirin in the treatment of arteriovenous fistula thrombosis

目的:分析氯吡格雷联合低分子肝素和拜阿司匹林治疗动静脉内瘘血栓形成的临床疗效。方法:选定本院收治的动静脉内瘘血栓形成患者60例,研究时段为2015年7月~2018年7月,在随机数表法的分组原则下,分为试验组(30例,氯吡格雷、低分子肝素、拜阿司匹林联合治疗)、对照组(30例,尿激酶溶栓治疗),比较临床疗效。结果:试验组临床总有效率显著较对照组高,P<0.05(具有显著差异)。结论:氯吡格雷、低分子肝素、拜阿司匹林联合可有效改善动静脉内瘘血栓形成患者病情,且操作方便,值得借鉴。

Objective:To analyze the clinical efficacy of clopidogrel combined with low molecular weight heparin and aspirin in the treatment of arteriovenous fistula thrombosis. Methods:Sixty patients with arteriovenous fistula thrombosis were enrolled in our hospital.The study period was from July 2015 to July 2018. Under the grouping principle of random number table method,the test group(30 cases,chloropyridin) Gray,low molecular weight heparin,aspirin combined treatment,and control group(30 cases,urokinase thrombolytic therapy),compare clinical efficacy. Results:The total clinical effective rate of the experimental group was significantly higher than that of the control group,P<0.05(statistical difference). Conclusion:The combination of clopidogrel,low molecular weight heparin and aspirin can effectively improve the condition of patients with arteriovenous fistula thrombosis,and it is easy to operate and worth learning.